亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Epigenetics in AML

技術優勢: Assessing epimutations of DNMT3A in AML patients for: diagnosis, risk stratification, choice of therapeutic regimen
Cost-effective and simple
Epimutations in DNMT3A are found in 40% of AML patients. Almost always these patients lack genetic mutations

技術應用: The screening for aberrant DNA hypermethylation within DNMT3A provides a relatively simple and cost-effective diagnostic approach for AML. It may be used to select the best treatment for patients.

詳細技術說明: This method is based on the identification of aberrant hypermethylation at an internal promoter region of DNMT3A, which occurs in about 40% of AML patients. High DNAm levels at this site are particularly observed in samples from AML patients without genetic mutations in DNMT3A. Epimutations and mutations of DNMT3A are associated with related gene expression changes such as upregulation of the homeobox genes in HOXA and HOXB clusters. Furthermore, epimutations in DNMT3A are enriched in patients with poor or intermediate cytogenetic risk, and in patients with shorter event-free survival and overall survival. Taken together, aberrant DNA hypermethylation within the DNMT3A gene, in analogy to DNMT3A mutations, is frequently observed in AML and both modifications seem to be useful for risk stratification or choice of therapeutic regimen.

分類: - international:
C12Q1/6886
- cooperative:
C12Q1/6886 (EP); C12Q2600/106 (EP); C12Q2600/154 (EP)

欲了解更多信息，請點擊這裡